U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...

US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to ...

US health officials are reviewing a nearly $600 million contract awarded to Moderna for bird flu vaccines in the final days ...

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

Moderna’s reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...